SEC Probes Matrixx Following FDA Zicam Warning

By Shannon Henson

Law360, New York (June 24, 2009, 12:00 AM ET) -- The U.S. Securities and Exchange Commission has asked Matrixx Initiatives Inc. to turn over documents and information related to the U.S. Food and Drug Administration's warning that a few of the company's Zicam Cold Remedy products cause consumers to lose their sense of smell.

In a filing with the SEC on Tuesday, Matrixx said it had received an informal inquiry requesting "certain documents and information" related to the FDA's June 16 warning letter. Matrixx said it would fully cooperate with the SEC.

Matrixx said Wednesday that...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles